U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Mammosomatotroph Pituitary Neuroendocrine Tumor

MedGen UID:
313410
•Concept ID:
C1708927
•
Neoplastic Process
Synonyms: Mammosomatotroph Adenoma; Mammosomatotroph PitNET/Adenoma; Mammosomatotroph Pituitary Gland Adenoma; Mammosomatotroph Pituitary Neuroendocrine Tumor/Adenoma

Definition

A pituitary neuroendocrine tumor composed of acidophilic cells that produce both growth hormone and prolactin. Immunohistochemical studies reveal the presence of these two hormones localized in the same cell. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMammosomatotroph Pituitary Neuroendocrine Tumor

Professional guidelines

PubMed

Role of mTOR Inhibitors in Growth Hormone-Producing Pituitary Adenomas Harboring Different FGFR4 Genotypes.
Jalali S, Monsalves E, Tateno T, Zadeh G
Endocrinology 2016 Sep;157(9):3577-87. Epub 2016 Jun 7 doi: 10.1210/en.2016-1028. PMID: 27267848
Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.
Kreutzer J, Vance ML, Lopes MB, Laws ER Jr
J Clin Endocrinol Metab 2001 Sep;86(9):4072-7. doi: 10.1210/jcem.86.9.7819. PMID: 11549628

Recent clinical studies

Etiology

Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
Durmuş ET, Atmaca A, Kefeli M, Çalışkan S, Mete O, Aslan K, Fidan M, Çolak R, Durmuş B
Growth Horm IGF Res 2022 Dec;67:101502. Epub 2022 Sep 9 doi: 10.1016/j.ghir.2022.101502. PMID: 36115256
Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL, Mete O, Perry A, Osamura RY
Endocr Pathol 2022 Mar;33(1):6-26. Epub 2022 Mar 15 doi: 10.1007/s12022-022-09703-7. PMID: 35291028
Follicular cells in pituitary neuroendocrine tumors.
Delfin L, Mete O, Asa SL
Hum Pathol 2021 Aug;114:1-8. Epub 2021 May 12 doi: 10.1016/j.humpath.2021.05.002. PMID: 33991528
Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up.
Lv L, Jiang Y, Yin S, Hu Y, Chen C, Ma W, Jiang S, Zhou P
Endocrine 2019 Nov;66(2):310-318. Epub 2019 Jul 31 doi: 10.1007/s12020-019-02029-1. PMID: 31368083
GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors.
Mete O, Kefeli M, Çalışkan S, Asa SL
Mod Pathol 2019 Apr;32(4):484-489. Epub 2018 Nov 2 doi: 10.1038/s41379-018-0167-7. PMID: 30390035

Diagnosis

Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
Durmuş ET, Atmaca A, Kefeli M, Çalışkan S, Mete O, Aslan K, Fidan M, Çolak R, Durmuş B
Growth Horm IGF Res 2022 Dec;67:101502. Epub 2022 Sep 9 doi: 10.1016/j.ghir.2022.101502. PMID: 36115256
Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL, Mete O, Perry A, Osamura RY
Endocr Pathol 2022 Mar;33(1):6-26. Epub 2022 Mar 15 doi: 10.1007/s12022-022-09703-7. PMID: 35291028
Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors.
Turchini J, Sioson L, Clarkson A, Sheen A, Gill AJ
Endocr Pathol 2020 Jun;31(2):150-155. doi: 10.1007/s12022-020-09615-4. PMID: 32193825
GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors.
Mete O, Kefeli M, Çalışkan S, Asa SL
Mod Pathol 2019 Apr;32(4):484-489. Epub 2018 Nov 2 doi: 10.1038/s41379-018-0167-7. PMID: 30390035
Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.
Cheng S, Al-Agha R, Araujo PB, Serri O, L Asa S, Ezzat S
PLoS One 2013;8(9):e73543. Epub 2013 Sep 9 doi: 10.1371/journal.pone.0073543. PMID: 24039977Free PMC Article

Therapy

Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
Durmuş ET, Atmaca A, Kefeli M, Çalışkan S, Mete O, Aslan K, Fidan M, Çolak R, Durmuş B
Growth Horm IGF Res 2022 Dec;67:101502. Epub 2022 Sep 9 doi: 10.1016/j.ghir.2022.101502. PMID: 36115256
Neural network modeling for prediction of recurrence, progression, and hormonal non-remission in patients following resection of functional pituitary adenomas.
Shahrestani S, Cardinal T, Micko A, Strickland BA, Pangal DJ, Kugener G, Weiss MH, Carmichael J, Zada G
Pituitary 2021 Aug;24(4):523-529. Epub 2021 Feb 2 doi: 10.1007/s11102-021-01128-5. PMID: 33528731
Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas.
Zhang D, Way JS, Zhang X, Sergey M, Bergsneider M, Wang MB, Yong WH, Heaney AP
J Clin Endocrinol Metab 2019 Jun 1;104(6):1929-1936. doi: 10.1210/jc.2018-02461. PMID: 30624667
Inactivation of transcription factor pit-1 to target tumoral somatolactotroph cells.
Roche C, Rasolonjanahary R, Thirion S, Goddard I, Fusco A, Figarella-Branger D, Dufour H, Brue T, Franc JL, Enjalbert A, Barlier A
Hum Gene Ther 2012 Jan;23(1):104-14. doi: 10.1089/hum.2011.105. PMID: 21942649
Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.
Kreutzer J, Vance ML, Lopes MB, Laws ER Jr
J Clin Endocrinol Metab 2001 Sep;86(9):4072-7. doi: 10.1210/jcem.86.9.7819. PMID: 11549628

Prognosis

Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
Durmuş ET, Atmaca A, Kefeli M, Çalışkan S, Mete O, Aslan K, Fidan M, Çolak R, Durmuş B
Growth Horm IGF Res 2022 Dec;67:101502. Epub 2022 Sep 9 doi: 10.1016/j.ghir.2022.101502. PMID: 36115256
Follicular cells in pituitary neuroendocrine tumors.
Delfin L, Mete O, Asa SL
Hum Pathol 2021 Aug;114:1-8. Epub 2021 May 12 doi: 10.1016/j.humpath.2021.05.002. PMID: 33991528
Neural network modeling for prediction of recurrence, progression, and hormonal non-remission in patients following resection of functional pituitary adenomas.
Shahrestani S, Cardinal T, Micko A, Strickland BA, Pangal DJ, Kugener G, Weiss MH, Carmichael J, Zada G
Pituitary 2021 Aug;24(4):523-529. Epub 2021 Feb 2 doi: 10.1007/s11102-021-01128-5. PMID: 33528731
Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up.
Lv L, Jiang Y, Yin S, Hu Y, Chen C, Ma W, Jiang S, Zhou P
Endocrine 2019 Nov;66(2):310-318. Epub 2019 Jul 31 doi: 10.1007/s12020-019-02029-1. PMID: 31368083
Epidemiology and biomarker profile of pituitary adenohypophysial tumors.
Mete O, Cintosun A, Pressman I, Asa SL
Mod Pathol 2018 Jun;31(6):900-909. Epub 2018 Feb 12 doi: 10.1038/s41379-018-0016-8. PMID: 29434339

Clinical prediction guides

Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
Durmuş ET, Atmaca A, Kefeli M, Çalışkan S, Mete O, Aslan K, Fidan M, Çolak R, Durmuş B
Growth Horm IGF Res 2022 Dec;67:101502. Epub 2022 Sep 9 doi: 10.1016/j.ghir.2022.101502. PMID: 36115256
Neural network modeling for prediction of recurrence, progression, and hormonal non-remission in patients following resection of functional pituitary adenomas.
Shahrestani S, Cardinal T, Micko A, Strickland BA, Pangal DJ, Kugener G, Weiss MH, Carmichael J, Zada G
Pituitary 2021 Aug;24(4):523-529. Epub 2021 Feb 2 doi: 10.1007/s11102-021-01128-5. PMID: 33528731
Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up.
Lv L, Jiang Y, Yin S, Hu Y, Chen C, Ma W, Jiang S, Zhou P
Endocrine 2019 Nov;66(2):310-318. Epub 2019 Jul 31 doi: 10.1007/s12020-019-02029-1. PMID: 31368083
Epidemiology and biomarker profile of pituitary adenohypophysial tumors.
Mete O, Cintosun A, Pressman I, Asa SL
Mod Pathol 2018 Jun;31(6):900-909. Epub 2018 Feb 12 doi: 10.1038/s41379-018-0016-8. PMID: 29434339
Light and electron microscopic observation of the same mammosomatotroph cell in a mixed growth hormone- and prolactin-secreting pituitary adenoma--case report.
Kabuto M, Kubota T, Kobayashi H, Nakagawa T
Neurol Med Chir (Tokyo) 1993 Apr;33(4):238-41. doi: 10.2176/nmc.33.238. PMID: 7685856

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...